Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hidden heart vessel damage may explain type 2 heart attacks

NCT ID NCT05793567

Diagnosis Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 31, 2026 · Last updated Sep 01, 2026 · Updated 1 time

Summary

Researchers at Mayo Clinic are testing whether people who have a type 2 heart attack, without major blockages in the large heart arteries, are more likely to have disease in the tiny blood vessels of the heart. The study uses a special X-ray procedure called coronary reactivity testing, which checks how these small vessels respond to three drugs. Participants include both type 2 heart attack patients and control patients with atypical chest pain. The goal is to see if measuring coronary flow reserve can reveal microvascular disease that standard tests might miss.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Coronary angiogram with coronary reactivity testing (CRT), an X-ray procedure that examines small heart blood vessels and their response to three drugs: adenosine, acetylcholine, and nitroglycerin.
What this could lead to
If it works, this could help doctors identify hidden small vessel disease in type 2 heart attack patients, leading to better treatments and prevention of future events.
What could go wrong
This is a small, early diagnostic study, not a treatment trial. The procedure carries risks like any angiogram, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 52 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects receiving care at Mayo Clinic in Rochester, MN identified with T2MI and controls with atypical chest pain with indication for CMD testing will be enrolled in this study. Both groups will have no epicardial coronary stenosis \>50% or obstructive disease.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ability to give informed consent * Structurally normal heart (normal LV and RV function, no more than mild valvular heart disease) * For controls: atypical chest pain with indication for CMD testing * For T2MI: meet criteria for T2MI according to the 4th Universal definition of MI (rise/fall of troponin with at least 1 value \>99th centile+ evidence of symptoms or signs of myocardial ischemia) Exclusion Criteria: * Acute coronary event (evidence of plaque rupture, fissure or dissection on coronary angiogram) * Known to have angiographically significant CAD/pressure wire positive for epicardial CAD * Inability to receive heparin products * Allergy/contraindication to acetylcholine/adenosine/nitroglycerine products * Prior coronary artery bypass grafting * Pregnancy (if sexually active woman of reproductive age, need negative pregnancy test prior to proceeding with coronary angiography - this is standard of care in cath lab) * Asthma with prior ICU admission due to bronchospasm/need for invasive ventilation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary microvascular disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary microvascular disorder Microvascular Angina myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary microvascular disease Myocardial infarction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Mayo Clinic Rochester

    Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.